BIIB vs HOTH · P/E 21, rev $9.89B vs rev $1.24B
Biogen Inc (BIIB) versus Hoth Therapeutics Inc (HOTH) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ.
Hoth Therapeutics Inc (HOTH) is a biotechnology company listed on US.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported HOTH revenue for 2024-03-31 was $1.24B. Net income was -$2.1M. HOTH currently screens at market cap $15.5M.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. HOTH currently screens at market cap $15.5M.
Not investment advice. Open the BIIB and HOTH stock pages for the full models.
Not investment advice.